Oxolamine (citrate)
Names
[ CAS No. ]:
1949-20-8
[ Name ]:
Oxolamine (citrate)
[Synonym ]:
CITRATO OXOLAMINA
OXOLAMINE CITRATE SALT
2,4-oxadiazole,5-(2-(diethylamino)ethyl)-3-phenyl-citrate
oxolamine dihydrogen citrate
OXOLAMINE CITRATE
OxolaminCitrate
5-[2-(DIETHYLAMINO)ETHYL]-3-PHENYL-1,2,4-OXADIAZOLE CITRATE
Oxolamine (citrate)
Biological Activity
[Description]:
[Related Catalog]:
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.066g/cm3
[ Boiling Point ]:
364.8ºC at 760 mmHg
[ Melting Point ]:
153-154ºC
[ Molecular Formula ]:
C20H27N3O8
[ Molecular Weight ]:
437.44400
[ Flash Point ]:
174.4ºC
[ Exact Mass ]:
437.18000
[ PSA ]:
174.29000
[ LogP ]:
1.37240
[ Vapour Pressure ]:
1.64E-05mmHg at 25°C
[ Storage condition ]:
2-8℃
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- RO0720000
- CHEMICAL NAME :
- 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, citrate
- CAS REGISTRY NUMBER :
- 1949-20-8
- LAST UPDATED :
- 199712
- DATA ITEMS CITED :
- 8
- MOLECULAR FORMULA :
- C14-H19-N3-O.C6-H8-O7
- MOLECULAR WEIGHT :
- 437.50
- WISWESSER LINE NOTATION :
- T5NO DNJ C2N2&2 ER &QV1XQVQ1VQ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1650 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 16,209,1961
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 351 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Discontinued. Volume(issue)/page/year: #683M
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 650 mg/kg
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - inflammation, necrosis, or scarring of bladder
- REFERENCE :
- THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 19,631,1964
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 351 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 16,209,1961 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 43400 mg/kg/7W-I
- TOXIC EFFECTS :
- Liver - changes in liver weight Kidney, Ureter, Bladder - changes in kidney weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
- REFERENCE :
- EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 7177 mg/kg/7W-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of salivary glands Kidney, Ureter, Bladder - inflammation, necrosis, or scarring of bladder Nutritional and Gross Metabolic - weight loss or decreased weight gain
- REFERENCE :
- EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963 ** TUMORIGENIC DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 15 gm/kg/1Y-I
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - Kidney tumors
- REFERENCE :
- EMPSAL Experimental and Molecular Pathology, Supplement. (New York, NY) No.1-3, 1963-66. Discontinued. Volume(issue)/page/year: 2,1,1963 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 120 mg/kg
- SEX/DURATION :
- female 9-11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 17,781,1967
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H302
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xn: Harmful;
[ Risk Phrases ]:
R22
[ RIDADR ]:
NONH for all modes of transport
[ RTECS ]:
RO0720000
Articles
Clin. Ter. 100(5) , 485-92, (1982)
Hallucinations in children caused by oxolamine citrate.
Med. J. Aust. 150(8) , 449-50, 452, (1989)
Twenty reports in Australia, Belgium and The Netherlands have implicated oxolamine-citrate cough-mixtures as a cause of hallucinations in children of less than 10 years of age. Fever is not thought to...
Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.J. Microencapsul. 9(2) , 167-72, (1992)
One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel. How...